Reperfusion of Pulmonary Arteriovenous Malformations Treated by Catheter Embolization
Author Information
Author(s): Bianca Gulich, Arno Buecker, Guenther Schneider
Primary Institution: Clinic of Diagnostic and Interventional Radiology, Saarland University Medical Center
Hypothesis
The study aims to evaluate patients with hereditary hemorrhagic telangiectasia (HHT) for potential reperfusion of pulmonary arteriovenous malformations (PAVM) treated by catheter embolization.
Conclusion
Regular lifelong follow-up studies after embolization are essential to detect reperfusion at an early stage and avoid serious complications.
Supporting Evidence
- Reperfusion was detected in 43 of 118 patients at follow-up.
- Thirty-five patients showed recanalization of the treated vessel.
- An enlarged diameter of the feeding artery was confirmed as a risk factor for reperfusion.
- The average time between embolization and detected reperfusion was 5.6 years.
- Regular follow-up is essential to avoid complications like brain abscess or stroke.
Takeaway
Doctors need to keep checking on patients who had their blood vessels treated because sometimes the problem can come back later.
Methodology
This retrospective study analyzed data from 345 patients screened for PAVM, with 118 patients included who underwent catheter embolization and had follow-up studies.
Potential Biases
The results may be influenced by data from patients treated externally, which could distort the overall findings.
Limitations
The retrospective design limited the collection of all parameters from every patient, and not all patients attended follow-up appointments regularly.
Participant Demographics
The average age of patients at embolization was around 42 years, with a female-to-male ratio of approximately 2:1.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website